Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • Depression
  • 62

Filter Results (13)

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    Assessment of Psilocybin Therapy for Treatment of Depression in Parkinson’s Disease

    Study Rationale: Depression is of the most common and disabling symptoms of Parkinson’s disease (PD), and it is linked to poor quality of life and faster disease progression. Unfortunately, we lack...

  • Diversity, Equity and Inclusivity in Parkinson's research, 2022
    Engaging the LGBTQIA+ Community, Caregivers and Care Providers in Research on Living with Parkinson’s Disease

    Study Rationale: Four million LGBTQIA+ adults age 50 and above live in the United States. We know very little about the needs of those in the LGBTQIA+ community who are living with Parkinson’s disease...

  • Therapeutic Pipeline Program, 2021
    Using Ketamine to Treat Depression in Parkinson’s Disease

    Study Rationale:
    Depression affects around half of people with Parkinson’s disease (PD). However, existing antidepressants are not effective in treating these symptoms in PD and new treatments are...

  • Research Grant, 2020
    Identification of Therapeutic Circuits to Address Anxiety and Depression Symptoms in Parkinson’s Disease

    Study Rationale: Parkinson’s disease patients often experience depression and anxiety. Addressing these non-motor symptoms has not been the focus of Parkinson’s disease research though psychiatric...

  • Therapeutic Pipeline Program, 2015
    Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach

    Study Rationale:                   
    There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)...

  • Repositioning Drugs for PD, 2012
    Amitriptyline as a Dopamine Neuroprotective Therapy

    Objective/Rationale:
    The project proposes to repurpose the tricyclic antidepressant medication, amitriptyline (AMI), as a disease-modifying therapy for Parkinson’s disease (PD). AMI is an FDA-approved...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.